# Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

> **NCT01473108** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 67 (actual)

## Conditions studied

- Clinical Pharmacology

## Interventions

- **DRUG:** Finerenone (BAY 94-8862) PEG solution
- **DRUG:** Finerenone (BAY 94-8862) immediate release tablet
- **DRUG:** Eplerenone (Inspra®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01473108
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-29
- **Primary completion:** 2010-11-30
- **Final completion:** 2011-05-17
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473108, "Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01473108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*